Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts

Metformin (MET) is a diabetes drug that activates AMP‐activated protein kinase (AMPK), and is suggested to have anticancer efficacy. Here, we investigated the role of AMPK signalling in prolactinoma (PRLoma), with particular respect to MET and bromocriptine (BC) as a PRLoma treatment. We analysed AM...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Cell Mol Med
Prif Awduron: Gao, Jun, Liu, Yang, Han, Gaijing, Deng, Kan, Liu, Xiaohai, Bao, Xinjie, Feng, Ming, Yao, Yong, Lian, Wei, Xing, Bing, Lv, Xiang, Wang, Renzhi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2018
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6237574/
https://ncbi.nlm.nih.gov/pubmed/30334324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.13963
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg